EGFR and head and neck squamous cell carcinoma: Thus, small molecular tyrosine kinase inhibitors (such as gefitinib) and monoclonal antibodies to EGFR (such as cetuximab) as a monotherapy have limited efficacy only in HNSCC patients (Bernier et al., 2009; Cohen et al., 2005; Vermorken et al., 2007).